The Moving Average Convergence Divergence (MACD) for CERS turned positive on May 23, 2023. Looking at past instances where CERS's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 25, 2023. You may want to consider a long position or call options on CERS as a result. In of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
CERS moved above its 50-day moving average on June 06, 2023 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CERS advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CERS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CERS broke above its upper Bollinger Band on June 06, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CERS entered a downward trend on May 30, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.758) is normal, around the industry mean (28.921). P/E Ratio (0.000) is within average values for comparable stocks, (142.211). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.647). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (2.875) is also within normal values, averaging (57.088).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CERS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CERS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of the INTERCEPT Blood System for platelets and plasma
|MFs / NAME||Price $||Chg $||Chg %|
|Fidelity® Select Medical Tech and Devcs|
|Hotchkis & Wiley Value Opps Instl|
|Delaware Ivy Small Cap Growth Y|
|Columbia Real Estate Equity C|
|CRM All Cap Value Inv|
A.I.dvisor indicates that over the last year, CERS has been loosely correlated with ATRC. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then ATRC could also see price increases.
|ATRC - CERS|
|CUTR - CERS|
|RVTY - CERS|
|TWST - CERS|
|ISRG - CERS|